Drug
AL 3789 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 2
- first study started
- 2003
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2003 (1)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2008 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 1
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses AL 3789 is read from its arms, and is right about nine times in ten.
Testing it · 3
- Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMDTerminatedPhase 3Alcon ResearchNCT00065728Written as Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL
- 24 Hour IOP Lowering Efficacy of AL-3789CompletedPhase 2Alcon ResearchNCT00643669Written as AL-3789 Sterile Suspension
- Anecortave Acetate Risk-Reduction Trial (AART)TerminatedPhase 3Alcon ResearchNCT00307398Written as Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg